Reimagine Medicine | Novartis

Media Release
Nov 28, 2023
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Media Release
Nov 09, 2023
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
Media Release
Oct 31, 2023
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Media Release
Oct 30, 2023
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Media Release
Oct 24, 2023
Novartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht
Media Release
Oct 24, 2023
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
Media Release
Oct 24, 2023
Novartis : hausse de 12% du chiffre d’affaires et de 21% du résultat opérationnel core (tcc¹). Spin-off de Sandoz, étapes importantes de l’innovation ; hausse des prévisions pour 2023
Media Release
Oct 23, 2023
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
Media Release
Oct 20, 2023
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Media Release
Oct 05, 2023
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Media Release
Oct 04, 2023
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
Media Release
Oct 02, 2023
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)